Compare CPHC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHC | BMEA |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1M | 85.3M |
| IPO Year | 2016 | 2021 |
| Metric | CPHC | BMEA |
|---|---|---|
| Price | $16.84 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 1.6K | ★ 918.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $59,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $523.00 | ★ N/A |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $14.49 | $0.87 |
| 52 Week High | $21.61 | $2.99 |
| Indicator | CPHC | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 51.91 |
| Support Level | $16.03 | $1.23 |
| Resistance Level | $17.42 | $1.46 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 74.99 | 91.26 |
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.